CALL - SPRINTER OPEN END - GILEAD SCIENCES | Real-time Bid/Ask 08:57:40 2024-06-27 EDT | ||
| 1.08 EUR / 1.1 EUR | -0.91% |
|
| Current month | +89.66% | ||
| 1 month | +54.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 1.09 | -0.91% |
| 24-06-26 | 1.1 | -2.65% |
| 24-06-25 | 1.13 | -11.02% |
| 24-06-24 | 1.27 | +4.10% |
| 24-06-21 | 1.22 | +20.79% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 08:46 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VA87VT |
| ISIN | DE000VA87VT4 |
| Date issued | 2018-11-01 |
| Strike | 57.97 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.37 € |
|---|---|
| Lowest since issue | 0.33 € |
| Spread | 0.02 € |
| Spread % | 1.82% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.31
USD
Average target price
82.97
USD
Spread / Average Target
+19.70%
- Stock Market
- Certificates
- Certificat
